NMI Protein, Mouse (His)

NMI proteins are signaling pathway regulators in the innate immune system, interacting with STATs in the presence of IL2 and IFN-γ to activate downstream genes. It enhances the recruitment of STAT1 and STAT5 by CBP/p300 coactivators, thereby increasing the transcription of dependent genes. NMI Protein, Mouse (His) is the recombinant mouse-derived NMI protein, expressed by E. coli , with C-6*His labeled tag.

NMI Protein serves as a signaling pathway regulator involved in the innate immune system response. In the presence of interleukin 2 (IL2) and interferon IFN-gamma (IFNG), NMI interacts with signal transducer and activator of transcription (STAT), activating downstream genes crucial for development and homeostasis. It enhances the recruitment of CBP/p300 coactivators to STAT1 and STAT5, resulting in increased transcription of STAT1- and STAT5-dependent genes. In response to interferon IFN-alpha, NMI forms a complex with the transcriptional regulator IFI35, preventing the proteasome-mediated degradation of IFI35 and regulating immune response. Additionally, NMI negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation and activation of NF-kappa-B subunit p65/RELA, impacting endothelial cell processes. It also plays a role in limiting virus-triggered type I interferon production by inducing the degradation of IRF7. Extracellularly, NMI functions as damage-associated molecular patterns (DAMPs), promoting inflammation when released by macrophages during injury or pathogen invasion. Macrophage-secreted NMI activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4 (TLR4) binding, inducing the release of pro-inflammatory cytokines. NMI interacts with various transcription factors, including MYCN, MYC, and STAT proteins, and undergoes ubiquitination mediated by TRIM21.

Mouse

E. coli

C-6*His

O35309 (M1-I314)

64685

Full Length.

MDADKDNIKQACDERSAEMDDMRGEQSMGLVHEIMSENKELDEEIKKLEAELQSDAREFQIKENVPEKKLKLTSVESPKDGCHFSNSSCSFQVSSQILYELQEGQALITFEKEEVAQNVISMGNHVVQMEGTPVKVSAHPVPLNTGVRFQVHVDISKMKINVTGIPDELSEEQTRDKLELSFCKSRNGGGEVESVDYDRKSRSAVITFVETGVVDKILKKKTYPLYMNQKCHSVAVSPCIERCLEKYQVFSAVSKKTVLLTGLEGIPVDEETGEDLLNIHFQRKNNGGGEVEVVKCSLDQSFAAYFKEEARETI

Approximately 40 kDa, based on SDS-PAGE under reducing conditions.

• 
  ≥ 95%, as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.